Enanta Pharmaceuticals | ENTA - Operating Expenses


Enanta Pharmaceuticals reported $126.59M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
AbbVie USD 10.52B 258M Sep/2026
Amgen USD 5.69B 6B Sep/2026
Anika Therapeutics USD 137.28M 3.38M Jun/2026
Arrowhead Research USD 245.35M 30.35M Jun/2026
AstraZeneca USD 11.55B 674M Sep/2026
BioCryst Pharmaceuticals USD -397.38M 517.17M Sep/2026
Biogen USD 2.32B 663.6M Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Gilead Sciences USD 13.04B 9.09B Sep/2026
GlaxoSmithKline GBP 6.03B 227M Sep/2026
Halozyme Therapeutics USD 198M 4.66M Sep/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Immunic USD 23.33M 2.67M Dec/2025
Incyte USD 5.64B 4.67B Sep/2026
Insmed USD 606.26M 79.46M Sep/2026
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
J&J USD 18.93B 1.09B Sep/2026
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
Ligand Pharmaceuticals USD 94.5M 39.4M Sep/2026
Merck USD 10.75B 5.02B Sep/2026
Neurocrine Biosciences USD 779.7M 40.6M Sep/2026
Novartis USD 9.88B 325M Sep/2026
Novavax USD 126.2M 23.62M Dec/2025
Pfizer USD 89B 3.81B Sep/2026
PTC Therapeutics USD 211.54M 15.12M Jun/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sarepta Therapeutics USD 390.39M 2.43M Sep/2026
Vertex Pharmaceuticals USD 2.18B 118.2M Sep/2026